The reasoning behind decisions not to take up antiretroviral therapy in Australians infected with HIV

2000 ◽  
Vol 11 (6) ◽  
pp. 361-370 ◽  
Author(s):  
R S Gold ◽  
J Hinchy ◽  
C G Batrouney

A substantial minority of HIV-infected Australians are not taking antiretroviral drugs. This study investigated the reasons behind their decision not to do so. Anyone who was HIV-infected but not taking antiretroviral drugs could participate. A self-administered, anonymous questionnaire was used, the principal recruitment method being through insertion of the questionnaire into gay community newspapers in Sydney and Melbourne. All respondents were asked questions covering demographics, previous AIDS-defining illnesses, T-cell and viral load monitoring, and previous use of antiretroviral drugs. In addition, respondents who had considered going on antiretroviral treatment, but then decided not to do so, were given a list of possible reasons for their decision and asked to indicate how much each played a role in their thinking. Of the 270 respondents, the great majority were gay men. One-eighth had experienced AIDS-defining illnesses. Two-thirds had recently had T-cell and viral load tests. One-third had taken antiretroviral drugs previously. Over two-thirds had considered antiretroviral therapy, most having given the matter quite some thought. Reasons for not taking up therapy did not differ greatly at different stages of HIV disease. The most common individual reason was fear of side effects. Important themes that emerged from factor analysis of the reasons data included distrust of conventional medical approaches to treatment, practical problems associated with taking antiretroviral drugs, unpleasant thoughts that being on therapy would evoke, and acceptance of the idea of dying. The findings can be used by doctors and counsellors to help patients clarify and evaluate their concerns about antiretroviral therapy.

2002 ◽  
Vol 29 (3) ◽  
pp. 270-274
Author(s):  
Christine Laine ◽  
Daozhi Zhang ◽  
Walter W. Hauck ◽  
Barbara J. Turner

BMJ ◽  
2011 ◽  
Vol 343 (nov09 2) ◽  
pp. d6884-d6884 ◽  
Author(s):  
J. G. Kahn ◽  
E. Marseille ◽  
D. Moore ◽  
R. Bunnell ◽  
W. Were ◽  
...  

PLoS ONE ◽  
2010 ◽  
Vol 5 (11) ◽  
pp. e15051 ◽  
Author(s):  
Vanja Romih ◽  
Snježana Židovec Lepej ◽  
Kornelija Gedike ◽  
Davorka Lukas ◽  
Josip Begovac

2019 ◽  
Vol 71 (4) ◽  
pp. 1017-1021
Author(s):  
Victor Ssempijja ◽  
Martha Nason ◽  
Gertrude Nakigozi ◽  
Anthony Ndyanabo ◽  
Ron Gray ◽  
...  

Abstract Background After scale-up of antiretroviral therapy (ART), routine annual viral load monitoring has been adopted by most countries, but reduced frequency of viral load monitoring may offer cost savings in resource-limited settings. We investigated if viral load monitoring frequency could be reduced while maintaining detection of treatment failure. Methods The Rakai Health Sciences Program performed routine, biannual viral load monitoring on 2489 people living with human immunodeficiency virus (age ≥15 years). On the basis of these data, we built a 2-stage simulation model to compare different viral load monitoring schemes. We fit Weibull regression models for time to viral load >1000 copies/mL (treatment failure), and simulated data for 10 000 individuals over 5 years to compare 5 monitoring schemes to the current viral load testing every 6 months and every 12 months. Results Among 7 monitoring schemes tested, monitoring every 6 months for all subjects had the fewest months of undetected failure but also had the highest number of viral load tests. Adaptive schemes using previous viral load measurements to inform future monitoring significantly decreased the number of viral load tests without markedly increasing the number of months of undetected failure. The best adaptive monitoring scheme resulted in a 67% reduction in viral load measurements, while increasing the months of undetected failure by <20%. Conclusions Adaptive viral load monitoring based on previous viral load measurements may be optimal for maintaining patient care while reducing costs, allowing more patients to be treated and monitored. Future empirical studies to evaluate differentiated monitoring are warranted.


AIDS ◽  
2012 ◽  
Vol 26 (11) ◽  
pp. 1403-1413 ◽  
Author(s):  
Janne Estill ◽  
Cindy Aubrière ◽  
Matthias Egger ◽  
Leigh Johnson ◽  
Robin Wood ◽  
...  

2021 ◽  
Vol 70 (21) ◽  
pp. 775-778
Author(s):  
Shirley Lee Lecher ◽  
Peter Fonjungo ◽  
Dennis Ellenberger ◽  
Christiane Adje Toure ◽  
George Alemnji ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document